Glargine is one of 83 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
150 competitors in Type 2 Diabetes Mellitus
DWP16001
Maridebart Cafraglutide
Retatrutide
Elecoglipron
Ganagliflozin
Imeglimin
Dorzagliatin
Adenocard
NOVOLIN R
Dostinex
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Sources